Immix Biopharma Analyst Ratings
Immix Biopharma Analyst Ratings
While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a reiterated with a price target of $0.00 to $14.00. The current price Immix Biopharma (IMMX) is trading at is $1.84, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 660.91% | Roth MKM | → $14 | Reiterates | Buy → Buy |
| 02/22/2023 | 660.91% | Roth MKM | → $14 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/14/2023 | 660.91% | Roth MKM | → 14 美元 | 重申 | 購買 → 購買 |
| 02/22/2023 | 660.91% | Roth MKM | → 14 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Immix Biopharma (IMMX)?
Immix Biopharma（IMMX）的目標價格是多少？
The latest price target for Immix Biopharma (NASDAQ: IMMX) was reported by Roth MKM on August 14, 2023. The analyst firm set a price target for $14.00 expecting IMMX to rise to within 12 months (a possible 660.91% upside). 2 analyst firms have reported ratings in the last year.
Roth MKM於2023年8月14日公佈了Immix Biopharma（納斯達克股票代碼：IMMX）的最新目標股價。這家分析公司將目標股價定爲14.00美元，預計IMMX將在12個月內升至12個月內（可能上漲660.91％）。去年有2家分析公司公佈了評級。
What is the most recent analyst rating for Immix Biopharma (IMMX)?
分析師對Immix Biopharma（IMMX）的最新評級是多少？
The latest analyst rating for Immix Biopharma (NASDAQ: IMMX) was provided by Roth MKM, and Immix Biopharma reiterated their buy rating.
Immix Biopharma（納斯達克股票代碼：IMMX）的最新分析師評級由Roth MKM提供，Immix Biopharma重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Immix Biopharma (IMMX)?
Immix Biopharma（IMMX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immix Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immix Biopharma was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Immix Biopharma的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Immix Biopharma的最後一次評級是在2023年8月14日提交的，因此您應該預計下一個評級將在2024年8月14日左右公佈。
Is the Analyst Rating Immix Biopharma (IMMX) correct?
分析師對Immix Biopharma（IMMX）的評級正確嗎？
While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a reiterated with a price target of $0.00 to $14.00. The current price Immix Biopharma (IMMX) is trading at is $1.84, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Immix Biopharma（IMMX）評級得到了重申，目標股價爲0.00美元至14.00美元。Immix Biopharma（IMMX）目前的交易價格爲1.84美元，在分析師的預測區間內。
